STAT3 and neoplasm: Our observations of comparable levels of pSTAT3 between healthy and tumor tissues and a lack of correlation with MVD or mature DC infiltration do not support the implementation of STAT3 inhibitors as anti-angiogenic or immunostimulatory therapeutics in NSCLC.